Filsuvez gel for epidermolysis bullosa simplex blisters
Part of Genetic & congenital, Skin clinical trials.
This study tests whether a gel called Filsuvez helps heal blisters and sores in people with epidermolysis bullosa simplex (EBS). It might reduce pain and improve skin healing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of epidermolysis bullosa simplex (EBS).
- You have active blisters or sores covering at least 3% of your body surface area, with fresh blisters on about half of that area.
- You are not currently using other topical creams or medicated dressings on the treatment areas during the study.
- You have not used an investigational drug, systemic steroids, or antibiotics in the last month (or 14 days for topical steroids).
- You are not pregnant or nursing, and if you could become pregnant, you agree to use a reliable birth control method.
- You are in generally good health and do not have other skin conditions or infections that might interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicated cream called TolaSure on skin affected by epidermolysis bullosa simplex (EBS), a condition that causes fragile skin and blistering. The cream aims to reduce blistering and improve healing by targeting a faulty protein in the skin. It is for people with localized, intermediate, or severe EBS who are currently having active blistering.
This study tests whether a daily pill called apremilast can reduce the number of new blisters in people with a genetic form of EBS (epidermolysis bullosa simplex). If you get more than 3 new blisters per day and have a confirmed KRT5 or KRT14 mutation, this trial may be a good fit.
This study tests a medication called deucravacitinib for adults with rare genetic skin conditions that cause blisters or severe scaling. The goal is to see if it can reduce symptoms safely.
This trial tests a drug called efgartigimod (VYVGART) to see if it can lower harmful antibodies in people with certain blistering skin diseases—dystrophic epidermolysis bullosa (DEB) and epidermolysis bullosa acquisita (EBA). If you have these antibodies, this treatment might help reduce blistering.
This study tracks anyone with dystrophic or junctional epidermolysis bullosa who is using Filsuvez gel to see how often skin cancers appear. It is designed to understand the long-term safety of the treatment.
This early-stage study tests stem cell–derived “extra-cellular vesicles” (small natural cell packages) to help heal painful skin wounds in people with dystrophic epidermolysis bullosa (DEB). If you have suitable, untreated wounds and meet the safety requirements, you may be able to join and help researchers learn whether this treatment is beneficial.
Hear when a new Epidermolysis Bullosa Simplex trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.